share_log

Vivos Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Ionic Ventures, LLC(1.8%),Ionic Management, LLC(1.8%), etc.

Vivos Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Ionic Ventures, LLC(1.8%),Ionic Management, LLC(1.8%), etc.

Vivos Therapeutics | SC 13G/A：超過5%持股股東披露文件(修正)-Ionic Ventures, LLC(1.8%),Ionic Management, LLC(1.8%)等
美股SEC公告 ·  11/15 05:14

牛牛AI助理已提取核心訊息

Vivos Therapeutics, Inc., a company listed on the U.S. stock exchange, has experienced a significant change in its shareholder structure as reported in a recent filing with the Securities and Exchange Commission (SEC). The filing, an amended Schedule 13G/A, indicates that Ionic Ventures LLC, Ionic Management LLC, Brendan O'Neil, and Keith Coulston, collectively referred to as the Reporting Persons, have ceased to be the beneficial owners of more than five percent of Vivos Therapeutics' outstanding common stock. The amendment, dated September 30, 2024, updates the beneficial ownership information previously filed on September 24, 2024. The Reporting Persons now collectively own 83,000 shares, representing 1.8% of the company's common stock, based on 4,765,300 outstanding shares as reported in the company's prospectus supplement. This amendment serves as an exit filing for the Reporting Persons, indicating a reduction in their collective ownership stake below the five percent threshold that requires continued reporting under SEC rules.
Vivos Therapeutics, Inc., a company listed on the U.S. stock exchange, has experienced a significant change in its shareholder structure as reported in a recent filing with the Securities and Exchange Commission (SEC). The filing, an amended Schedule 13G/A, indicates that Ionic Ventures LLC, Ionic Management LLC, Brendan O'Neil, and Keith Coulston, collectively referred to as the Reporting Persons, have ceased to be the beneficial owners of more than five percent of Vivos Therapeutics' outstanding common stock. The amendment, dated September 30, 2024, updates the beneficial ownership information previously filed on September 24, 2024. The Reporting Persons now collectively own 83,000 shares, representing 1.8% of the company's common stock, based on 4,765,300 outstanding shares as reported in the company's prospectus supplement. This amendment serves as an exit filing for the Reporting Persons, indicating a reduction in their collective ownership stake below the five percent threshold that requires continued reporting under SEC rules.
vivos therapeutics公司是一家在美國交易所上市的公司，最近在證券交易委員會（SEC）的備案中報告了其股東結構的重大變化。該備案，即修訂後的Schedule 13G/A，顯示Ionic Ventures LLC、Ionic Management LLC、Brendan O'Neil和Keith Coulston被統稱爲報告人，已不再是vivos therapeutics已發行普通股超過5%的實益擁有者。該修訂日期爲2024年9月30日，更新了之前在2024年9月24日提交的實益所有權信息。報告人現在總共擁有83,000股，佔公司普通股的1.8%，基於公司招股說明書補充中報告的4,765,300股已發行股份。該修訂作爲報告人的退出備案，表明他們的集體所有權已降至低於5%的門檻，這要求根據SEC規則繼續報告。
vivos therapeutics公司是一家在美國交易所上市的公司，最近在證券交易委員會（SEC）的備案中報告了其股東結構的重大變化。該備案，即修訂後的Schedule 13G/A，顯示Ionic Ventures LLC、Ionic Management LLC、Brendan O'Neil和Keith Coulston被統稱爲報告人，已不再是vivos therapeutics已發行普通股超過5%的實益擁有者。該修訂日期爲2024年9月30日，更新了之前在2024年9月24日提交的實益所有權信息。報告人現在總共擁有83,000股，佔公司普通股的1.8%，基於公司招股說明書補充中報告的4,765,300股已發行股份。該修訂作爲報告人的退出備案，表明他們的集體所有權已降至低於5%的門檻，這要求根據SEC規則繼續報告。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間